Ovarian Tumor FAK Inhibition Releases Omega-3 Fatty Acids Stimulating GATA6 Peritoneal Macrophage CXCL13 Production Enhancing Immunotherapy

Genetic or pharmacolgic inhibition of Focal Adhesion Kinase in the murine KMF tumor model is compared to the growth of untreated tumors and with those treated with first line or second line chemotherapies. Impact upon the tumor subpopulations and immune compartment is evaluated via scRNAseq.. Overall design: KMF cells were seeded at 5 million per C57bl/6 mouse IP and mice were untreate or were treated serially with standard of care chemotherapy (platinum + taxane) or pegylated doxorubicin. Alternatively, mice were treated with an inhibitor of FAK (VS4718) or with cells deficient in FAK expression(KO) of catalytic activity(KD, Kinase dead).